Endometrial stromal sarcomas: a retrospective analysis of 28 patients, single center experience for 20 years.
OBJECTIVE
The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESSs) in relation to their clinical and pathogenic features, and to determine the optimal treatment strategy.


METHODS
A retrospective analysis was performed involving 28 patients with histologic-proven ESSs treated at our institution between 1987 and 2006.


RESULTS
The median follow-up was 54.7+/-63.1 months and the 5-year survival rate was 82.0%. Twenty-two (81.5%) and 5 patients (18.5%) had low- and high-grade disease, respectively. Univariate analysis revealed that the histologic grades, based on mitotic count, were associated with longer survival (p=0.004). However, among those patients with low-grade tumors, 5/20 patients (25%) had a recurrence and 2/21 patients (9.5%) had distant metastasis during the follow-up period. With the exception of 2 patients, 26 patients with ESSs underwent hysterectomy as primary treatment. Adjuvant treatment after surgery was administered to 14/26 patients (53.8%). Hormone therapy with progesterone, chemotherapy, and/or radiotherapy did not influence overall survival. However, the postoperative adjuvant therapy group, regardless of the treatment modality, was associated with relatively increased overall survival when compared to the surgery only group (p=0.054).


CONCLUSIONS
The preoperative differential diagnosis of ESSs from other benign gynecologic diseases is often difficult. We recommend adjuvant therapy be administered after hysterectomy in patients with ESS to prevent recurrence or distant metastasis.
Nam
Eun Ji
EJ
Women's Cancer Clinic, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Kim
Jae Wook
JW
Lee
Dae Woo
DW
Jang
Si Young
SY
Hong
Jong Wook
JW
Kim
Young Tae
YT
Kim
Jae Hoon
JH
Kim
Sunghoon
S
Kim
Sang Wun
SW
Gynecol Oncol. 2007 Jun;105(3):630-4
17320937
Gynecol Oncol. 1996 Nov;63(2):247-53
8910635
Eur Radiol. 2001;11(1):28-33
11194912
Gynecol Oncol. 1995 Aug;58(2):262-5
7622117
Cancer. 1990 Jul 1;66(1):35-9
2354406
Anticancer Drugs. 2000 Apr;11(4):275-8
10898543
Cancer. 1985 Apr 15;55(8):1648-53
3884128
Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):739-48
11172957
Cancer. 1966 Jun;19(6):755-66
5939046
Gynecol Oncol. 1990 Jan;36(1):113-8
2295442
Gynecol Oncol. 1990 Jan;36(1):60-5
2295453
Obstet Gynecol. 2005 Dec;106(6):1304-8
16319256
Eur J Obstet Gynecol Reprod Biol. 2003 Aug 15;109(2):209-13
12860344
Cancer. 1987 Oct 15;60(8 Suppl):2035-41
3652025
Gynecol Oncol. 1989 Dec;35(3):290-3
2689303
Gynecol Oncol. 1997 Feb;64(2):265-9
9038274
Br J Cancer. 2007 Nov 5;97(9):1194-9
17895898
Am J Surg Pathol. 1990 May;14(5):415-38
2327549
Gynecol Oncol. 2006 Jun;101(3):464-9
16368128
Gynecol Oncol. 2005 Feb;96(2):402-6
15661228
Gynecol Oncol. 2001 May;81(2):160-5
11330943
Obstet Gynecol. 1996 May;87(5 Pt 1):747-50
8677079
Gynecol Oncol. 2004 Nov;95(2):412-3; author reply 413
15491769
Eur J Obstet Gynecol Reprod Biol. 1991 Mar 21;39(1):63-9
2029958
Gynecol Oncol. 2003 Jul;90(1):170-6
12821359